

The Long Road to Culture of Embryos in a Safe Culture Medium: Synthetic Protein-Free Culture Medium (1985-2005)

Jaffar Ali, PhD
IVF Laboratory & Reprod Res Laboratories
Department of Obstet & Gynaecol
University of Malaya Medical Center
University of Malaya
Kuala Lumpur
Malaysia

Email: jaffarali@um.edu.my



Egg/Sperm/Embryo Handling & Culture Media

- Have you ever wondered:
 - what the handling & culture media **contains?**
 - Are its ingredients **safe?**
 - For your patients?
 - For the babies?
 - To yourself and other healthcare workers?
 - Is it defined and remains unaltered with every new batch?

Disadvantages of the Present-Day Embryo Culture Media

- Contains donor human/animal (in the past) serum proteins
- Or serum replacement products derived from human donors
- Not defined; batch to batch variation is common affecting quality of embryos generated;
- **may be hazardous** Risk of disease transmission by protein-bound agents (viruses/prions)

Sterilization not 100% efficacious

- **Proteins cannot be sterilized. Stringent purification and sterilization measures cannot eradicate with absolute certainty all unknown/known pathogens** (Truyen et al., 1995).

Extreme heat treatment may NOT DESTROY PRIONS

- **Proteins in culture medium - risk of disease transmission. e.g. HIV, Hepatitis, BSE/CJD, etc**

Kemmann, Hum Reprod 13: 1777, 1998

Donor Proteins in Culture Medium

- Proteins are non-uniform/ non-consistent because each batch is from different groups of donors
- **Regulatory profile**: PFM anticipated to comply with regulations

Disease Transmission in IVF

- At least **three documented cases** but many more; unreported Check out Medico-Legal Journals
- **Transmission of hepatitis** - Pooled sera - IVF >200 patients affected (van Os et al. 1991. Am J. Obstet. Gynecol. 165:152-159)
- **CJD?** - A donor of serum proteins for a media manufacturing company in USA died of CJD
- Extend of damage not known
- **CJD take as long as 20 years to manifest.** (Kemmann, 1998, Human Reprod. 13:1777)
- **Medico-legal cases – In medico legal journals numerous cases under pending judicial investigation**

European Union Tissue & Cell Directive 2004

EU Directive 2004/23/EC:

Urge member states to move away from use of non-uniform biological supplements (that creates batch variations) in healthcare products

Biologicals create possible contamination risk situations by pathogens, prions, RNA, DNA, other hitherto unknown agents, etc

- Members states must comply by April 2007

A major challenge to researchers & service providers alike.

Time-restricted urgency to seek for alternatives to the use of non-uniform biological supplements in health care products.

Advantageous to use safe and defined synthetic Protein-Free media

■ **MAKES SENSE TO ELIMINATE**

- Use of potentially hazardous donor serum or serum replacement substances derived from human donors

■ **COMPLETELY SYNTHETIC MEDIA**

- Will remain consistent and therefore there will be no batch to batch variation – there will be no variation in the quality of embryos generated

The Scenario in the 1980s

Scenario in the 1980s

- Pregnancy rate was a dismal **9 -15%**
- That means **85-91%** of the patients will **not become pregnant** after ART treatment
- Naturally most Governments refused support for ART because
 - it was expensive /not cost effective
 - not efficacious and
 - because there were urgent matters such as sanitation and basic healthcare facilities that needed attention compared to infertility.

Scenario in the 1980s

- **Reasons for the poor ART pregnancy rates** were multi-factorial
- But some of the main reasons were:
 - **Use of sub-optimal** tissue/mouse embryo culture media (not entirely meant for human application)
 - **Use of patient's own serum** in culture media that affected quality of embryos generated
 - **Lack of R&D** to develop embryo culture media specific for human embryos
 - Media was home-made and QC/QA was non-compliant/sub-optimal
- Clearly these sub-optimal conditions have to be overcome if we are going to equal or better the natural fecundity rate of 20%

Scenario in the 1980s

- We embarked on an extensive and meticulous R&D venture beginning 1985 to
 - Develop Embryo Culture Media (ECM) that is specific for:
 - (i) mammalian embryos
 - (ii) human embryos and thence develop
 - **A synthetic formulation** that is:
 - Completely defined
 - No batch to batch variation
 - Very efficacious
 - Completely safe for human application
 - That complies with healthcare regulations

PFM-11 Synthetic Protein-Free Media Products Outcome of 15-20 Years of Research

This research effort resulted in a synthetic ECM that is:


- Specific for human embryos
- Completely defined
- No batch to batch variation
- Very efficacious; better or similar current protein-containing ECM
- Appears very safe for human application
- That apparently complies with healthcare regulations

The subsequent slides will show how the PFM-11 media was formulated

Development of Synthetic Protein-Free Culture Medium:



Above: Human embryos generated in protein-free medium.
Below: Human embryos generated in protein-containing medium



Formulation of the Synthetic Protein-Free Medium (PFM-11)

- **Two main functions of proteins in culture:**
 - **1. Physiological attributes**
 - **2. Physical attributes**

Formulation of the Synthetic Protein-Free Medium (PFM-11)

Physical attributes in culture:

- 1. Viscosity to culture medium
- 2. Surfactant property
 - These properties allow the handling of embryos with ease and prevent embryos sticking to sides of dishes and in pipettes

Formulation of the Synthetic Protein-Free Medium (PFM-11)

Physiological Roles of Proteins

- **antioxidant & chelators of metal ions**
- **prevent membrane peroxidation/stabilize membranes**
- **source of energy**
- **capillary membrane permeability**
- **help solubilize lipids**
- **osmoregulation**
- **pH buffer**
- **transport of CO₂/hormones/vitamins/metals**
 - **serving as reservoirs for storage/release of**
 - **these components**

Role of proteins in Embryo culture medium: the prevailing wisdom

Is the presence of protein in CM a prerequisite for

- sperm capacitation?
- interaction of male and female gametes?
- fertilization and development of embryos?

Can absence of protein in CM cause ZP hardening?

- impair normal spermatozoa penetration?
- impair fertilization & development of embryos?
- impair normal zona hatching?

Formulation of the Synthetic Protein-Free Medium (PFM-11)

It is therefore clear that:

- No single substance can substitute serum proteins in culture media.
- However many components in appropriate combination/concentration may act synergistically to replace serum proteins

Plan of work

- Phase 1:** A systematic investigation to determine optimum concentration of various components normally found in the female reproductive tract and other components was undertaken using mouse zygote assay
[optimal conc. of individual components n=50 determined]
- Phase 2:** Based on these findings a number media were formulated and evaluated with mouse zygotes
- Phase 3:** The best of these media was then evaluated during routine human IVF procedures (medium contained HSA; Approved Trial)
- Phase 4:** Subsequently the protein in the medium was removed to create protein-free media evaluated with mouse embryos

Plan of work

- Phase 5:** Protein-free medium evaluated with human 1PN and 3PN embryos (Approved Trial)
- Phase 6:** Effect of protein-free medium on survival of the human spermatozoa for 48hrs (Approved trial)
- Phase 7:** The capability of the protein-free medium to support the development of viable human embryos was determined during routine IVF with & without cumulus co-culture (Approved Trial)
- Clin trial:** Human embryos generated in the protein-free medium was performed (Approved Trial)

Plan of work

Phase 1, Experiments 1-50

Determination of the Optimal concentration of about 50 components, namely:

- 1. A. Acids
 - 2. Anti-Oxidants (known & novel)
 - 3. Osmolytes
 - 4. Vitamins
 - 5. Alternate Energy sources
 - 6. Other components
 - Basal salt solution +BSA –
 - Tested on SO mice zygotes. End point: :blastocyst formation
- Duration: >3 years

Results


Phase 1: Experiments 1- 50

Determination of tolerance and optimal concentration of Individual components


Beyond scope/ time does not permit the presentation of results of experiments

The **optimal concentration** identified and used for formulating new media


Component 1



Component 26



Component 50



% Blastocysts

Plan of work

Phase 2

- Based on results of investigations in Phase 1 (Experiments 1-50), many media were formulated.
- Test Media:
 - **TEST-1** **TEST-2** **TEST-3**
- Evaluated with mouse zygotes and compared with
- Control medium:
 - CM1 (Commercial medium)

Results

Phase 2: Experiment 51

Table 1: Development of 1-cell mouse embryos in test and control media

Media	TEST-1	TEST-2	TEST-3	CM1	
% Blast	<u>97.3</u>	94.7	<u>98.2</u>	84.2	S
% Hatch	<u>78.8</u>	57.0	<u>72.6</u>	62.2	S 1

Blast=blastocyst formation; Hatch=blastocyst hatching

Plan of work

Phase 3

- The best media identified in Phase 2 (TEST Media-1&3) was then evaluated during routine human IVF procedures
- (Test Medium 6 contained HSA instead of BSA)
- Random selection all age groups
- Eggs fertilized/cultured in both test and control media. The best embryos selected irrespective media employed (Approved Trial)

Results

Phase 3: Experiment 54

Table 2: Comparison between TEST-6 and control media on the development of human day 2 embryos

Media	No. hEggs	Fertil Rate %	Arrest @ 1-cell %	Blastomere number Mean	Grade Mean
<u>TEST-6</u>	301	69.4	4.3S	2.9	3.3
CM1	370	71.6	7.3	3.1	3.0
CM2	374	70.1	8.8	3.2	3.0

[Embryo grade: 4=excellent; 3=good; 2= fair; 1=poor]

CM=Commercial medium

All media, test and controls, contained HSA

Results

Phase 4: Experiment 55

Table 3: Development of late 2-cell mouse embryos when cultured in media supplemented with and without protein

Description	No. of 2-cell Mouse embryos	% Blastulation & Hatching/Hatched
TEST-6 Med (+ protein)	66	95.5
TEST-6 Med (- protein)	69	100.0
		p=0.2274

Plan of work

Phase 5

Protein-free medium evaluated with Human Embryos (Approved Trial)

- Preliminary Human Test Material 1PN & 3PN
- Protein-free medium was evaluated with human 1PN and 3PN (abnormal) embryos

Results

Phase 5: Experiment 57

Table 4: Evaluation of protein-free medium on 1PN and 3PN human embryos

Stage of Development	No. of embryos	% cleavage
Day 1 (1-Cell Stage)	n=24	-
Day 2 (2- to 6-Cell)	n=24	100
Day 3 (8-Cell)	n=23	95.8
Day 4 (12- to 16-cell)	n=21	87.5
Day 5 (compacted morula)	n=7	29.2
Day 6/7 (early blastocyst)	n=3	12.5 (poor)
Day 7 (expanded blastocyst)	n=0	0

Finding comparable to previous reports on media containing proteins

Plan of work

Phase 6

Effect of protein-free medium on survival of the human spermatozoa for 48hrs

- To determine response of human spermatozoa to PF medium
- Control media : Commercial medium CM1

Results

Phase 6: Experiment 58

Table 5: Human sperm survival characteristics in control medium CM1 and the protein-free media

Medium	0hr mil/mL Mean	No.	24hr (% Survival at 37°C) Mean	48hr Mean
PF Medium	6.6	22	79.0	41.7
Control CM1	5.1	22	50.1	26.2
Significance			p=0.0113	p=0.2141

(Individual semen specimen was portioned equally for test and control groups; only normal specimen used)

Plan of work

Phase 7

- Phase 7.1
- The capability of the protein-free medium to support the development of human embryos was determined during routine ART procedures
- Random selection all age groups
- Eggs fertilized/cultured in both test and control media. The best embryos selected irrespective media employed (Approved Trial)

Phase 7.2: Quality of day 2 human sibling embryos generated by conventional IVF in protein-free medium

Medium	Fertil %	Arrested @ 1-cell stage %	Blast number Mean (1SD)	Grade Mean (1SD)	% ≥ 4 cells	% ≥3 Grade
Protein-Free Med (- protein)	85.3 (116/136)	2.2	3.4 (1.0)	3.1 (0.9)	58.4	74.3
Medi-Cult (+ protein)	79.2 (118/149)	8.1	3.4 (1.0)	2.7 (0.8)	56.2	58.1
Significance	p=0.235	p=0.052	p=0.865	<u>p=0.001</u>	p=0.847	<u>p=0.017</u>

[Embryo grade: 4=excellent; 3=good; 2= fair; 1=poor]
 Control embryos generated by ICSI or IVF
 Blast = blastomere

Results

Phase 7.1: Experiment 59

Table 6: Quality of day 2 human sibling ICSI embryos when cultured in PF and control media

Medium	Fertilization Rate %	Blastomere number Mean (SE)	Grade Mean (SE)	No. of cleaved embryos
PF Medium	87.1 (27/31)	2.7 (0.225)	3.6 (0.163)	27
Control CM1	74.5 (35/47)	3.2 (0.215)	3.2 (0.169)	34*
Signif.	p=0.7785	p=0.3581	p=0.2141	

[Embryo grade: 4=excellent; 3=good; 2= fair; 1=poor]

- * All zygotes cleaved in PF medium but 1 arrested in Control medium

Plan of work

Phase 7

Phase 7.3

- Cumulus co-culture was employed to determine whether the PF was deficient
- If deficient, to further improve the quality of the PF medium to generate quality embryos

Results

Phase 7.3: Experiment 60

Table 7: Quality of day 2 human sib. embryos cultured in Protein-free medium with cumulus co-culture and control media

Medium	Fertilization Rate		Arrested @ 1-cell stage Mean	Blastomere no. Mean	Grade
	%	%			
PF Med+CC	69.9	(51/73)	0	3.5	3.3
Cont. CM1	55.1	(54/98)	11.1*	2.8	2.7
Signif.	p=0.0715		p=0.0290	p=0.0358	p=0.0164

[Embryo grade: 4=excellent; 3=good; 2= fair; 1=poor] *6 arrested at zygote stage

Plan of work

Phase 7

Phase 7.3

- Cumulus co-culture (i) tedious and time consuming, (ii) potential for contamination, and is (iii) not chemically defined
- 16 further modifications were tested to formulate another protein-free medium to eliminate the need for cumulus co-culture

Results

Phase 8: Experiment 63

Table 8: Quality of day 2 human sibling embryos generated by conventional IVF or ICSI in protein-free medium

Medium	Fertil %	Arrested @ 1-cell stage %	Blast number Mean	Grade Mean	% ≥ 4 cells	% ≥ 3 Grade
PF medium (- protein)	80.4 (320/398)	2.8	3.7	3.0	65.0	68.0
Control CM2 (+ protein)	73.1 (293/401)	7.0	3.4	2.8	55.4	58.4
Significance	<u>p=0.0178</u>	<u>p=0.0092</u>	<u>p=0.001</u>	<u>p=0.0007</u>	<u>p=0.022</u>	<u>p=0.021</u>

[Embryo grade: 4=excellent; 3=good; 2= fair; 1=poor] Culture technique: ULTRA MICRO-DROPLET, Ali et al., 2000

First pregnancies/births from embryos generated in synthetic protein-free medium, 1997/2000

The births of babies generated from the fertilization of eggs collected and inseminated in synthetic PFM using spermatozoa also prepared in the same protein-free medium

(Ali J, Shahata MAM., Al-Natsha SD.
Formulation of a protein-free medium for human assisted reproduction.
Hum. Reprod. Jan 2000, 15: 145-156).

Results

Phase 8: Clinical trial

Table 9: Summary of Embryos Transferred, Implantation, Viability and Delivery Rates of Embryos Generated in Protein-Free Medium

Description	Protein-free	Control Medium (CM2)
Total no. of Patients	114	1515
No. of Patients Clin Pregnant (all ages)	55 (48.2%; S)	469 (31.0%)
No. of Clin..Preg Patients lost to Follow-up:	5	16
No. of Patients That Aborted	12 (24%; S)	150 (n=453; 33.1%)
No. of Patients That Delivered	38	303
% pregnancies that went to term	76% (38/50; S)	66.9% (303/453)
Delivery Rate	35% (38/109; S)	20.2% (303/1499)
Total No. of Embryos Transferred	358	
Average No. of Embryos Transferred:	3.1	~3.0
Implantation Rate:	25% (83/358)	
No. of Babies Delivered	53 (2 tripl; 13 tw.; 21 singl.)	
Embryo Viability Rate:	14.8% (53/ 358)	

Results

Phase 8: Clinical trial

Table 6: Summary of clinical pregnancies from day 2 embryos generated in the protein-free medium (Age factor)


CPR in women 39 years and below	54.7% (52/95)
CPR in women 40yrs and above	15.8% (3/19)
CPR Overall (all age groups)	48.2% (55/114)

(CPR = Clinical Pregnancy Rate = +ve Sac & FHB)

The protein-free medium appears to be similar to or better than media containing proteins

Efficacy of the Protein-Free medium Muneera's Babies

- 6 of 7 eggs fertilized by ICSI in PF medium
- 5 of 6 eggs fertilized by IVF in PF medium
- 3 day 2 ICSI (4/5-cell) embryos > ET
- Positive blood test, 3 sacs seen/ +ve FH
- 3 boys delivered, now 9 yrs old



Independent evaluation of PFM

- The protein-free medium will be/is being independently evaluated in a number of labs worldwide
- Evaluated with excellent outcome for mouse embryos in the USA
- Multicentre IUI clinical trial on PFM currently ongoing in India with excellent outcome – 26% PR

The PFM-11 Synthetic ECM is UNIQUE

- Unique because a completely different approach was taken in its formulation/development and contains components not found in standard ECM.
- Contains a macromolecule “MetCel” that is very safe. MetCel has been used as a
 - food thickener for over 30yrs,
 - in ocular solutions for 25 yrs or more with no adverse reports.
 - a negative control in cancer research as it is non-teratogenic/non-carcinogenic
 - is an antioxidant
- Contains a unique sugar component “MT”.
 - Saturated MT was/is used for clinical application with no adverse outcome.
 - An antioxidant,
 - enhances embryo development by a presently unknown mechanism (antioxid?)

Previous reports on protein-free embryo culture

- Mouse: Brinster, 1960s, Cholewa and Whitten, 1970, Mehta and Kiessling 1990, Spindle, 1995
- Rabbit: Li et al., 1996
- Primates: Schramm and Bavister, 1996
- Human: Ali, 1997-8,9, 2000, 02a,b, 03, 06 (Abst),
Ali et al. 2000,01,04, 06
 - Mohr & Trounson, 1986; Serta Kiessling 1997 (Abst);
Parinaud et al. 1999– BUT proteins used for sperm prep/fertilization

Summary of Overall Results

1. Fertilization rate,
2. quality of embryos,
3. implantation rate &
4. zona hatching **NOT IMPAIRED IN PF Medium**
 - clinical pregnancy rate
 - and live birth rate in PF medium are similar to or better than those generated in media containing serum proteins

Conclusion

- We now have an efficacious (Regulation-compliant?, GMP-compliant?) protein-free (PFM-11) medium for human ART
- Approval for certification compliance pending with FDA and EU
- The PFM-11 appears to be SAFE.
- Excellent clin. pregnancy rate of 55% in women <39
- Children born from embryos generated in the PFM are now about 9 to 13 years old and apparently normal and healthy
- The PFM-11 is the product of a long, meticulous and systematic investigation and is thus anticipated to meet the expectations of ART workers
- PFM Reproducible/No batch to batch variation
- Potential for transmission of protein-bound pathogens to IVF patients can now be eliminated
- No longer dependent on serum proteins

Acknowledgement

- **My mentors**
- **Dr Jim Shelton, PhD, DVSc**
- **(Late) Dr Wes Whitten, DSc, FA**
- **Dr Peter McCullagh, MBBS, DPhil**
- **John Curtin School of Medical Research Australian National University**
- **Others: individuals/institutions**
- **Investigation took years of prime family time.**
- **My family for their patience**
- **THANK YOU**



5/21/2013

49